Mirum Pharmaceuticals (MIRM) Operating Expenses (2019 - 2026)

Mirum Pharmaceuticals' Operating Expenses history runs 8 years deep, the most recent figure standing at $949.3 million for Q1 2026.

• In Q1 2026, Operating Expenses rose 648.89% year-over-year to $949.3 million; the TTM figure through Mar 2026 stood at $1.4 billion (up 199.85% YoY), while the FY2025 annual figure was $543.4 million, up 28.02% from the prior year.
• Operating Expenses for Q1 2026 stood at $949.3 million, up from $153.5 million in the prior quarter.
• The five-year high for Operating Expenses was $949.3 million in Q1 2026, with the low at $45.6 million in Q1 2022.
• The 5-year median for Operating Expenses is $102.1 million (2024), against an average of $142.4 million.
• The sharpest annual moves came in 2022 and 2026: Operating Expenses retreated 4.17% in 2022, then surged 648.89% in 2026.
• Mirum Pharmaceuticals' Operating Expenses stood at $62.1 million in 2022, then soared by 64.56% to $102.1 million in 2023, then advanced by 21.05% to $123.6 million in 2024, then rose by 24.15% to $153.5 million in 2025, then soared by 518.47% to $949.3 million in 2026.
• Business Quant data shows MIRM's Operating Expenses at $949.3 million in Q1 2026, $153.5 million in Q4 2025, and $130.4 million in Q3 2025.